Treatment News : Study Confirms That Early HIV Treatment Preserves Immune Function

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 28, 2010

Study Confirms That Early HIV Treatment Preserves Immune Function

People who start antiretroviral (ARV) therapy within six months of HIV infection retain immunity to other pathogens better than people who start treatment later, according to researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The data, published online September 13 in the journal Blood, add to evidence that those living with HIV fortunate enough to be diagnosed within a few months of contracting the virus may benefit from immediate ARV treatment.

A number of studies from the past 15 years suggest important clinical benefits to starting ARV treatment very soon after infection. While the vast majority of people living with HIV are diagnosed several months, or even years, after contracting the virus, some individuals are diagnosed and enter care within weeks or a few months of infection.

If HIV is diagnosed and treated soon after infection is established, some researchers have suggested, it may be possible to protect cells capable of fighting HIV and other disease-causing pathogens.

B cells are a vital part of the immune system. They produce antibodies that target foreign organisms for destruction by other immune cells. Many of the B cells, and the antibodies they produce, are specific to only one type of pathogen. Vaccines take advantage of this. When we’re vaccinated against a disease, the vaccine prompts B cells to recognize parts of a pathogen and make antibodies. After an initial burst of activity, the B cells go into a resting state so that they are ready to wake up and quickly produce lots of antibodies as soon as we are exposed to the actual pathogen. Resting B cells can persist for many years.

To determine the impact of early ARV treatment on B cell preservation, Susan Moir, PhD, and her colleagues from NIAID compared B cell number and function in three groups: HIV-negative men, HIV-positive men who started ARVs within six months of infection and HIV-positive men who started ARVs many months or years after infection. The study looked backward, or retrospectively, at data that had already been collected for other studies.

Moir’s team found that before the two groups of HIV-positive men started treatment, both had poor B cell function and lower B cell numbers than HIV-negative men. After the HIV-positive men started treatment, however, the difference in both B cell number and function between those who started treatment within six months of infection and those who started later was striking.

Whereas the early treatment group saw their B cell number and function go back to similar levels as the HIV-negative men, those who started later had persistently lower and more poorly functioning B cells.

One way that Moir and her colleagues measured B cell function was to look at how well the three groups of men responded to influenza vaccination at the beginning of the study period—for the HIV-positive men this was just before starting ARVs—and then one year later. At the beginning of the study, both groups of HIV-positive men had poorer vaccine responses. A year after starting ARVs, however, men who’d started treatment early had normal vaccine responses, while those who started treatment later had persistently lower vaccine responses.

The authors stated that these data support recommendations to start treatment very early. They added: “These findings provide new insights on B cells in HIV infection and how early initiation of ART may prevent irreversible immune system damage.”

Search: Early treatment, antiretroviral, ARV, B cell, antibody, vaccine, Susan Moir


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    Newhopenate
    New Hope
    Pennsylvania


    youngbloodlatino
    Columbia
    Maryland


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.